Talking on the ET World Townhall, the biopharma sector entrepreneur mentioned the nation’s science laboratories have already proven super potential in growing Covid-19 testing kits in the course of the previous 3-Four months.
“Because of India’s vaccine trade, the (upcoming) vaccine (for Covid-19) won’t be the prerogative and protect of the prosperous Western world…Serum Institute has already partnered with Oxford College effectively earlier than AstraZeneca took over that programme. So Indian vaccine producers can play a really huge position,” mentioned Mazumdar-Shaw.
She added that India’s healthcare sector would be the subsequent to realize international recognition after the IT companies trade.
“Life science is an innovation alternative for India which we’ve got not leveraged in the suitable approach. Right now, the highlight is on the sector. I’m positive we’re going to be very a lot a part of the worldwide provide chain for healthcare. India has an enormous alternative to be an essential a part of the world’s healthcare useful resource,” she mentioned.
The Biocon chief mentioned it was time the nation moved forward with “a way of confidence and resilience” to rebuild healthcare, to be able to assist India grow to be a worldwide chief within the sector.
Mazumdar-Shaw mentioned the Covid-19 pandemic has additionally prompted the nation to open up the medical analysis area. “We’ve to rebuild the medical analysis sector. This was a thriving sector 10 years in the past.”